The literature reviews from Semmelweis researchers found that in particular, protein, omega-3 polyunsaturated fatty acids, and vegetables appear to benefit COPD patients. “Changing the diet from ...

There are several tests that doctors can use to diagnose and monitor COPD. Let's take a look at what abnormal values for ...

Maintaining a healthy lifestyle through nutrition and exercise becomes even more crucial during pregnancy with COPD. Eating a well-balanced diet that includes fresh fruits and vegetables can help ...

COPD cases among younger individuals are on the rise due to factors such as smoking, vaping, air pollution, and exposure to ...

The U.S. Food and Drug Administration has approved Dupixent (dupilumab) to reduce COPD exacerbations in some patients whose symptoms aren’t adequately controlled with inhaled medicines.

The drug was cleared for use in adults whose COPD symptoms aren’t under control and whose disease is driven by eosinophils, a type of immune cell that can contribute to inflammation. There are ...

All had received a diagnosis of either dementia, heart attack, chronic obstructive pulmonary disease (COPD) or colon cancer ...

Treatment with dupilumab reduced the annualized rate of moderate or severe COPD exacerbations by 30% in the BOREAS trial and 34% in the NOTUS trial compared with placebo. The Food and Drug ...

After 12 weeks of nebulized NAC, patients’ mean phlegm scores, as measured by the COPD assessment test, significantly decreased from 3.47 at baseline to 2.62. N-acetylcysteine (NAC) nebulizer ...

This approval was based on results from the phase 3 BOREAS (NCT03930732) and NOTUS (NCT04456673) trials, which demonstrated that dupilumab can significantly reduce COPD exacerbations. 2 The first ...

Over the last decade, as other companies—such as AstraZeneca with IL-5 inhibitor Fasenra—struggled to advance candidates for COPD, Regeneron and Sanofi took a more “phenotype-driven approach ...

The FDA has granted a supplementary approval to Regeneron and Sanofi’s dupilumab (Dupixent) for use as an add-on therapy for inadequately controlled chronic obstructive pulmonary disease (COPD ...